Skip to main content
. Author manuscript; available in PMC: 2015 Sep 15.
Published in final edited form as: J Immunol. 2014 Aug 18;193(6):3080–3089. doi: 10.4049/jimmunol.1303196

Figure 6.

Figure 6

ORF-9b uses PCBP2/AIP4 to degrade MAVS and to impair type I interferon responses. (A) Immunoblot of lysates from HEK 293 cells expressing Myc-MAVS and either GFP or 9b-GFP in the presence of a control shRNA or a shRNA targeting either PCBP2 or AIP4. (B) Immunoblot of cell lysates and PCBP2 immunoprecipitates (+) from HEK 293 cells expressing GFP or 9b-GFP. Cells were treated with MG-132 (10 μM) for 2 h prior to lysis. Mock is a control antibody immunoprecipitation. (C) IFN-β and NF-κB reporter assays using HEK 293 cells expressing GFP or 9b-GFP along with a control, PCBP2, or AIP4 shRNA and induced by transfection of Poly(I:C). The luciferase activity shows in fold induction. **p<0.01, statistics analyzed by t test.